S chentag et al. 1 vigorously advocate the use of AUC 24 / minimum inhibitory concentration (MIC) >125 for fluoroquinolones in order to achieve bacteriologic eradication against all target organisms and in all hosts. Their argument faces opposition from other groups in the field of pharmacodynamics. 2 However, we welcome debate in the scientific arena because such dialogue opens the door for better understanding of fluoroquinolone pharmacokinetics/pharmacodynamics. Schentag et al.'s arguments attract attention to some important issues that necessitate further investigation and discussion concerning the way we design our in vitro modeling experiments, set study endpoints, define antibiotic break points, interpret results, and consider how antibiotic-resistant mutants develop within a bacterial population. Examination of and reflection on pharmacodynamic concepts may provide better approaches to designing in vitro and animal studies, as well as clinical trials, so that fluoroquinolones can be modeled to achieve maximum bacterial eradication (hopefully with acceptable toxicity) and optimal prevention of the development of bacterial resistance.
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We all agree that for fluoroquinolones, AUC 24 /MIC, and maximum concentration (C max )/MIC are the best predictors of microbiologic and, less so, clinical outcome. However, some important issues need to be considered to arrive at an optimal approach and draw conclusions from our in vitro modeling studies.
First, it is time to realize that different fluoroquinolone AUC 24 /MIC (not simply AUC 24 /MIC >125) ratios are required for eradication and prevention of resistance in different organisms (e.g., Streptococcus pneumoniae, Pseudomonas aeruginosa). This has been well described previously 3,4 and confirmed by MacGowan et al. 5 As well, we need to realize that the immune system in an immunocompetent host may directly or indirectly lower the AUC 24 /MIC ratios required for bacterial eradication, potentially to varied degrees, depending on the organism.
Second, since only the unbound fraction of the drug is biologically active, 6,7 only the unbound (non-protein bound) fraction of the drug should be used in pharmacodynamic calculations. Thus, we should consider only the unbound drug AUC 24 /MIC and unbound drug C max /MIC pharmacodynamic predictors. This issue was made clear by Mouton et al. 8 in their efforts to standardize pharmacokinetic/pharmacodynamic terminology for antiinfective drugs.
Third, it is important to set and interpret adequate antibiotic break points. Mouton 9 elegantly discussed methods to determine clinical break points and recognized the fact that those break points should be used to predict the success of therapy; microbiologic break points should have the capacity to distinguish between antibiotic naïve populations and resistant subpopulations. In the case of fluoroquinolone-resistant S. pneumoniae, clinical break points may capture 2step mutations (parC, gyrA), which are associated with clinical failure, while microbiologic break points would capture 1-step (e.g., parC or potentially gyrA) changes that may develop into future 2-step mutants.
Fourth, more attention should be paid for adequate quantification of the bacterial killing/regrowth curve. A fresh look at the work of Firsov et al. 10-14 may lead to more appropriate in vitro model experimental design and better quantification of the antimicrobial effect. One review addressed different endpoints and predictors of antimicrobial effect, as well as typical pitfalls inherent in determination and interpretation. 10 It is clear that the use of optimal endpoints and predictors of the effect is decisive in comparative pharmacodynamics of the newly developed antibiotics, the selection of the most potential compounds, and the prediction of their pharmacodynamic predictors and doses. We also believe that careful attention to study design, time-related events, adequate endpoints, and adequate predictors might reconcile many of the present controversies and disagreements. We encourage more experimentation designed to validate or question the Firsov et al. approach.
Schentag et al. effectively argue that surveillance programs with fluoroquinolones that simply report the percent susceptible, intermediate, and resistant S. pneumoniae based on break points do not accurately inform us of emerging resistance. They suggest that surveillance studies need to be performed in centers or communities with high use of fluoroquinolones and that MIC distributions be detailed to allow the observation of MIC population shifts. We agree and applaud them for these comments. As well, Schentag et al. state that Canada has one of the best surveillance systems in the world, which, along with extensive fluoroquinolone use, make this country an ideal testing ground for fluoroquinolone MIC shifts over time. We describe such a surveillance system and its most recent findings.
Our Canadian Respiratory Organism Susceptibility Study (CROSS) is a continuous ongoing longitudinal surveillance program that evaluates the incidence of antibiotic resistance in respiratory pathogens across all regions of Canada. 15, 16 Thus, it represents a unique opportunity to compare antibiotic resistance among various geographically distributed medical centers, patient demographic profiles, and antimicrobial classes. From 1997 to 2002, the same 25 medical centers participated in all 5 years of the study. Each year, large numbers (1180-1593) of respiratory isolates of S. pneumoniae were isolated and collected during the same time period (winter months). Over the study period, the demographics remained constant in that the specimen type was primarily sputum, bronchoalveolar lavage specimens, and endotracheal secretions. Isolates tested were approximately 54% inpatient and 46% outpatient. The gender breakdown was approximately 40% female and 60% male, and the age breakdown was approximately 20% ≤16 years of age, 40% 17-64 years of age, and 40% ≥65 years of age. For the fluoroquinolones, the order of activity based on MIC 50 and MIC 90 values was gemifloxacin ≥ clinafloxacin > trovafloxacin > moxifloxacin ≥ grepafloxacin > gatifloxacin > levofloxacin > ciprofloxacin. Resistance to newer fluoroquinolones such as levofloxacin (intermediate, resistant) was 0.8%, highest in penicillin-resistant S. pneumoniae and in the elderly (≥65 y old). No MIC shift with levofloxacin occurred over the 5-year period. Although this study clearly showed no shift in fluoroquinolone MICs over time, we agree with Schentag et al. that ongoing surveillance studies must continuously evaluate MIC distributions to assess shifts over time.
Schentag et al. discuss that Hong Kong surveillance studies have described high rates (~12%) of fluoroquinolone resistance in S. pneumoniae. 17 This observation is true and begs the questions of why resistance is so high in Hong Kong and whether the same situation will occur in North America. Reasons for the level of fluoroquinolone-resistant S. pneumoniae being so high in Hong Kong include high rates of fluoroquinolone or other antibiotic use per capita, over-the-counter availability of antibiotics, use of low doses of fluoroquinolones (e.g., ciprofloxacin, levofloxacin, ofloxacin 100 mg orally 3 times/d), high population density, and clonal spread. Will this situation occur in North America? Although it has been reported that fluoroquinolone-resistant S. pneumoniae in Canada are not clonally related, 18 we believe that the same situation can happen in North America, if we adopt antibiotic usage patterns similar to those in Hong Kong or, more importantly, if we continue to use fluoroquinolones such as ciprofloxacin that are not able to effectively eradicate S. pneumoniae (due to low AUC 24 /MIC) and readily select for both low-level (efflux and/or parC mutations) and high-level (parC and gyrA) mutants.
We have previously discussed that ciprofloxacin is not very effective in eradicating S. pneumoniae and readily selects for both low-and high-level resistant mutants. 19, 20 Also, although ciprofloxacin is susceptible to efflux by S. pneumoniae, the new fluoroquinolones gatifloxacin, levofloxacin, and moxifloxacin are not. 21 Although low-level fluoroquinolone-resistant mutants are frequently susceptible to all of the new fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin), once high-level resistance occurs, these isolates must be considered cross-resistant to all fluoroquinolones. One frequently cited article from Canada illustrates the problem with ciprofloxacin. 22 From 1988 to 1998, the level of fluoroquinolone-resistant S. pneumoniae dramatically escalated to the highest rates in the world. This occurred due to the enormous use of ciprofloxacin for the empiric treatment of community-acquired respiratory illnesses such as pneumonia, acute exacerbations of chronic bronchitis, and sinusitis, where S. pneumoniae is a frequent pathogen. In fact, the use of ciprofloxacin for the treatment of community-acquired respiratory infections represents approximately 70% of all ciprofloxacin use in Canada. Due to low AUC 24 /MIC obtained with ciprofloxacin versus S. pneumoniae, resistance occurred rapidly. During this time, none of the new fluoroquinolones were available for use in Canada. Unfortunately, this drastically inappropriate use of ciprofloxacin has continued. Even today, ciprofloxacin is by far the most frequently used fluoroquinolone in both outpatient and inpatient practice (>2:1 vs. all other fluoroquinolones combined). This has led to the creation of a country with a large pool of S. pneumoniae with parC mutations that now has resulted in clinical failure even with the new fluoroquinolones.
One report described 4 clinical failures due to levofloxacin. 23 Why did these failures occur? Could they have been prevented? Upon close inspection, 2 of the patients had received prior ciprofloxacin therapy and clinically and bacteriologically had failed that treatment. Why would a ciprofloxacin failure (knowing that these patients likely had parC and gyrA mutations) receive another fluoroquinolone rather than a different class of antibiotics (e.g., a cephalosporin with a macrolide)? Using any new fluoroquinolone (after failing ciprofloxacin therapy in the empiric treatment of respiratory infection) is likely to result in treatment failure. 24 What about the other 2 patients; why did they fail therapy? One patient became infected with a parC S. pneumoniae presumably due to the vast pool of that mutation in Canada resulting from the inappropriate use of ciprofloxacin, and levofloxacin could not eradicate it. Is this surprising? No. Our own data suggest that, once a first-step mutation has developed, it is very easy for a second mutation to occur with any of the new fluoroquinolones, leading to high-level resistance to all fluoroquinolones. 25 This is best described by the markedly elevated mutant prevention concentrations (MPCs) with all fluoroquinolones that occur once a parC mutation is present. The fourth patient is the most interesting. This patient developed a double (parC, gyrA) mutation on therapy. The authors failed to explain this genetic dilemma, as the likelihood of this occurring is <1 × 10 -16 . This case becomes even more perplexing given that previous studies have reported that achieving unbound AUC 24 /MIC ≥30 (which would have occurred in both blood and epithelial lining fluid in this patient) with new fluoroquinolones in treating S. pneumoniae results in rapid bactericidal action. 19
Summary
It is clear that the major cause of the development and propagation of fluoroquinolone-resistant S. pneumoniae is the dramatic inappropriate overuse of ciprofloxacin, especially for empiric treatment of community-acquired respiratory illness, which is not very effective at eradicating S. pneumoniae (due to low AUC 24 /MIC) 17 and readily selects for both low-and high-level resistant mutants. 19 What can we do to prevent further increases in fluoroquinolone-resistant S. pneumoniae as well as clinical failures even with the new fluoroquinolones? We should stop using ciprofloxacin for community-acquired respiratory infections in favor of the newer fluoroquinolones that are less likely to select for resistance at the target site and also are not susceptible to efflux in S. pneumoniae and not use any fluoroquinolones in patients who have recently clinically and/or bacteriologically failed a fluoroquinolone or perhaps received a fluoroquinolone for any purpose in the last 3 months. We should aggressively encourage the judicious use of all antibiotics. We should insist that surveillance studies not only report percent susceptible, intermediate, and resistant, but also describe MIC distributions over time to assess MIC shifts. We should perform ongoing DNA sequencing (minimally of the Quinolone Resis-tance Determining Region) on randomly selected S. pneumoniae isolates with fluoroquinolone MICs around the break point to assess the accumulation of silent mutations. We will be able to curtail fluoroquinolone-resistant S. pneumoniae only through such an aggressive multi-pronged action plan.
